...
首页> 外文期刊>JAIDS: Journal of acquired immune deficiency syndromes >Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202
【24h】

Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202

机译:开始抗逆转录病毒治疗后,炎症标志物与艾滋病和非艾滋病临床事件的关系:艾滋病临床试验A5224s组(ACTG A5202的子研究)

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The association of inflammatory biomarkers with clinical events after antiretroviral therapy initiation is unclear. Methods: A5202 randomized 1857 treatment-naive subjects to abacavir/lamivudine or tenofovir-DF/ emtricitabine with efavirenz or atazanavir/ritonavir. Substudy A5224s measured inflammatory biomarkers on subjects with available plasma from baseline and week 24 or 96. An exploratory analysis of the association of highsensitivity C-reactive protein, interleukin-6 (IL-6), soluble receptors of tumor necrosis factor a (sTNF)-RI, sTNF-RII, TNF-a, soluble vascular cellular adhesion molecules (sVCAM-1), and soluble intercellular adhesion molecules (sICAM-1) with times to AIDS and to non-AIDS events used Cox proportional hazards models. Results: Analysis included 244 subjects; 85% men and 48% white non-Hispanic with median age 39 years, HIV-1 RNA of 4.6 log10 copies per milliliter, and CD4 of 240 cells per microliter. Overall, 13 AIDS events (9 opportunistic infections, 3 AIDS-cancers, and 1 recurrent bacterial pneumonia) and 18 non-AIDS events (6 diabetes, 4 cancers, 3 cardiovascular, and 5 pneumonias) occurred. Higher baseline IL-6, sTNF-RI, sTNF-RII, and sICAM-1 were significantly associated with increased risk of AIDS-defining events. Adjustment for baseline HIV-1 RNA did not change results, whereas adjusting for baseline CD4 count left only sTNF-RI and sICAM-1 significantly associated with increased risk. Time-updated values of IL-6, sTNFR-I and II, and sICAM-1 were also associated with an increased risk. For non- AIDS events, only higher baseline high-sensitivity C-reactive protein was significantly associated with increased risk, whereas higher IL-6 was marginally associated with higher risk. Analyses of timeupdated biomarker values showed tumor necrosis factor a to be significantly associated with increased risk, even after adjustment for antiretroviral therapy, and CD4 count or HIV-1 RNA. Conclusions: Higher levels of several inflammatory biomarkers were independently associated with increased risk of AIDS and non- AIDS events.
机译:背景:炎症生物标志物与抗逆转录病毒疗法启动后的临床事件之间的关联尚不清楚。方法:A5202将1857例初治患者随机分为阿巴卡韦/拉米夫定或替诺福韦-DF /恩曲他滨联合依非韦伦或阿扎那韦/利托那韦。研究A5224s从基线到第24周或第96周测量具有可用血浆的受试者的炎症生物标志物。对高敏C反应蛋白,白细胞介素6(IL-6),肿瘤坏死因子a(sTNF)可溶性受体的关联的探索性分析。 -CRI,sTNF-RII,TNF-α,可溶性血管细胞粘附分子(sVCAM-1)和可溶性细胞间粘附分子(sICAM-1)与AIDS和非AIDS事件相关的时间均使用Cox比例风险模型。结果:分析包括244名受试者; 85%的男性和48%的非西班牙裔白人,中位年龄为39岁,HIV-1 RNA 4.6 log10拷贝/毫升,CD4 240细胞/微升。总体而言,发生了13例AIDS事件(9例机会感染,3例AIDS癌症和1例复发性细菌性肺炎)和18例非AIDS事件(6例糖尿病,4例癌症,3例心血管疾病和5例肺炎)。较高的基线IL-6,sTNF-RI,sTNF-RII和sICAM-1与艾滋病定义事件的风险增加显着相关。调整基线HIV-1 RNA不会改变结果,而调整基线CD4计数仅使sTNF-RI和sICAM-1与风险增加显着相关。 IL-6,sTNFR-I和II和sICAM-1的时间更新值也与风险增加有关。对于非艾滋病事件,只有较高的基线高敏感性C反应蛋白与危险增加显着相关,而较高的IL-6与危险较高相关。对时间更新的生物标志物值的分析显示,即使在调整抗逆转录病毒疗法以及CD4计数或HIV-1 RNA之后,肿瘤坏死因子a也与增加的风险显着相关。结论:几种炎症生物标记物的较高水平与艾滋病和非艾滋病事件的风险增加独立相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号